CME description
CME credits: 0.25 Valid until: 02-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/Retina-Case-Review-Translating-the-Data-Into-Care/36108/ Wondering how your practice's use of next-generation retinal agents compares to the experts? Join Dr. Durga Borkar and Dr. Veeral Sheth as they discuss how they are using next-generation agents to free their patients from frequent office visits. =
CME credits: 1.00 Valid until: 11-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/program-name/35985/ Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.
CME credits: 1.00 Valid until: 11-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/program-name/35986/ Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.
CME credits: 1.00 Valid until: 11-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/program-name/35987/ Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.
CME credits: 1.00 Valid until: 11-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/program-name/35988/ Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.
CME credits: 1.00 Valid until: 11-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/program-name/35989/ Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.
CME credits: 1.00 Valid until: 11-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/program-name/35990/ Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.
CME credits: 1.00 Valid until: 11-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/program-name/35991/ Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.
CME credits: 1.00 Valid until: 11-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/program-name/35992/ Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.
CME credits: 1.00 Valid until: 11-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/program-name/35993/ Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.
CME credits: 0.50 Valid until: 17-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/contrasting-trop2-targeted-adcs-in-breast-cancer-therapy/33024/ This online chapterized CME activity features Drs. Kevin Kalinsky and Komal Jhaveri in a discussion on TROP2-targeted antibody-drug conjugates (ADCs) for metastatic breast cancer (mBC). The faculty describe the therapeutic role of TROP2 as well as both approved and investigational ADCs that target TROP2. Clinical trial data on TROP2-targeted ADCs from various studies are reviewed to evaluate their efficacy and safety across hormone receptor–positive and triple-negative disease settings. The discussion contrasts molecular structures, dosing schedules, and toxicity profiles of each ADC, providing insight into their positioning in treatment algorithms. Practical strategies for therapy sequencing, patient selection, and shared decision-making are emphasized throughout.=
CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-latest-patient-centered-recommendations-from-the-7th-world-symposium-on-ph/33236/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.
CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/managing-travel-with-pah-logistics-medications-oxygen-and-emergency-preparedness/33237/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.
CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/aligning-pah-treatment-plans-with-key-care-goals-and-your-patients-priorities/33238/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.
CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/integrating-palliative-care-in-pulmonary-hypertension/33239/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.
CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/patient-reported-outcome-measures-proms-valuable-insights-into-the-lived-experience-of-pah/33240/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.
CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/a-comparison-of-proms-and-how-to-use-them-in-clinical-practice-for-pah/33241/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.
CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/what-challenges-and-triumphs-do-patients-face-while-living-with-pah/33242/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.
CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/proms-in-clinical-practice-impacting-treatment-decisions/33243/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.
CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/proms-role-in-clinical-research-and-contributions-to-pah-patient-perspectives/33244/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.
CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/how-do-patient-experiences-and-pah-perspectives-vary-across-regions-and-cultures-worldwide/33245/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.
CME credits: 1.00 Valid until: 14-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/treatment-of-a-broader-population-of-patients-with-dmd/33167/ By completing this activity, learners will gain the skills and confidence to determine therapeutic candidacy and conduct appropriate assessments for patients with Duchenne Muscular Dystrophy (DMD) across the age spectrum, including older and non-ambulatory individuals. They will improve their ability to interpret and apply the latest clinical data to real-world scenarios and make informed decisions about treatment and monitoring. Through case-based education, learners will enhance their competence in aligning patients to appropriate therapies and managing long-term care in a rapidly evolving treatment landscape.=
CME credits: 0.50 Valid until: 14-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/chairpersons-perspective-precision-in-practice-advancing-egfr-altered-metastatic-nsclc-through-guideline-concordant-case-based-learning/33808/ This 30-minute Chairperson's Perspective program explores the evolving landscape of (epidermal growth factor receptor) EGFR-altered metastatic non–small cell lung cancer through guideline-concordant, evidence-based learning. Dr. Natasha Leighl reviews the clinical importance and optimal timing of molecular testing and provides evidence-based strategies for patient selection and treatment sequencing across EGFR mutation subtypes, including common mutations and exon 20 insertions. Emphasis will be placed on emerging therapies, key clinical trial data, and the integration of multidisciplinary care in managing adverse events associated with EGFR-targeted therapies.=
CME credits: 0.50 Valid until: 09-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/differentiating-neuromodulation-therapies-vns-dbs-ect-tms/35793/ This series of bite-sized episodes contains important information on using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) and treatment-resistant depression (TRD). Drs. Raman Sankar and Scott Aaronson discuss best practices for identifying and treating patients as well as programming strategies for VNS.
CME credits: 0.50 Valid until: 09-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/epilepsy-beyond-seizure-impact/35794/ This series of bite-sized episodes contains important information on using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) and treatment-resistant depression (TRD). Drs. Raman Sankar and Scott Aaronson discuss best practices for identifying and treating patients as well as programming strategies for VNS.
CME credits: 0.50 Valid until: 09-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/vns-beyond-seizure-control/35795/ This series of bite-sized episodes contains important information on using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) and treatment-resistant depression (TRD). Drs. Raman Sankar and Scott Aaronson discuss best practices for identifying and treating patients as well as programming strategies for VNS.
CME credits: 0.50 Valid until: 09-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/qol-matters-brain-stem-stimulation-in-patients-with-unipolar-depression/35796/ This series of bite-sized episodes contains important information on using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) and treatment-resistant depression (TRD). Drs. Raman Sankar and Scott Aaronson discuss best practices for identifying and treating patients as well as programming strategies for VNS.
CME credits: 0.50 Valid until: 09-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-vns-parameters-keys-to-therapeutic-success/35797/ This series of bite-sized episodes contains important information on using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) and treatment-resistant depression (TRD). Drs. Raman Sankar and Scott Aaronson discuss best practices for identifying and treating patients as well as programming strategies for VNS.
CME credits: 1.00 Valid until: 08-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/stemming-the-tide-on-masldmash-it-starts-on-the-frontlines-in-endocrinology-and-primary-care-clinics/35568/ The epidemic of metabolic dysfunction-associated liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) is fully upon the US healthcare system, and it's projected to get worse. The prevalence of MASLD in the US is expected to increase from 33.7% in 2020 to 41.4% in 2050, which translates to approximately 122 million adults being affected. Our broadcast on Global Fatty Liver Day provides practical and engaging discussions to help endocrinologists and primary care providers better understand the use of noninvasive tests and biomarkers for timely screening and primary risk assessment, treatment and management of cardiometabolic risk, and assignment to the appropriate level of care for patients with MASLD/MASH. =
CME credits: 1.00 Valid until: 03-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/pulmonary-hypertension-getting-the-right-diagnosis-and-knowing-when-to-refer/36094/ Pulmonary hypertension (PH) is a serious, progressive condition and the care pathways for patients who are living with Group 1 versus Group 2 PH can be very different. Join our experts as they discuss key elements for identifying which WHO Group your patient may fall into and review key factors for developing an effective treatment plan and knowing when to refer patients to other professionals that are part of the PH care team=
CME credits: 1.00 Valid until: 03-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/new-and-emerging-pah-therapies-and-approaches-a-mixture-of-hope-and-complexity/36095/ Pulmonary arterial hypertension (PAH) is a serious, progressive condition that involves making the correct diagnosis and identifying patient comorbidities as important first steps to creating a successful treatment approach. And while identifying which WHO Group a patient belongs to is key, part of the art of treating PAH is recognizing that many patients can have overlap between groups. Our experts' insights can help you elevate your practice and develop effective PAH treatment plans.=
CME credits: 1.00 Valid until: 03-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/ph-management-in-unique-patients-and-conditions/36096/ Pulmonary arterial hypertension (PAH) is a serious, progressive condition and successfully managing patients can present certain challenges. Treatment selection is multifactorial and often involves the consideration of myriad patient factors, including WHO Group, objective risk stratification score, cardiac functioning on imaging, and shared decision-making. And while all patients who are living with PAH require careful evaluation, those with comorbidities and/or psychosocial challenges can require additional consideration when developing a treatment plan that improves outcomes.=
CME credits: 1.00 Valid until: 20-06-2026 Claim your CME credit at https://reachmd.com/programs/cme/expert-perspectives-on-nonsteroidal-mras-and-cardiorenal-protection/32990/ Heart failure with mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF) represent a significant and growing burden for patients and the healthcare system, not only in cardiovascular medicine, but also in the context of cardio-kidney-metabolic (CKM) syndrome. Trials are underway evaluating new therapies that may offer benefits to patients with HFmrEF/HFpEF and may also have broader, multisystem effects. Tune in to stay up to date! =
CME credits: 1.00 Valid until: 11-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/taking-action-in-moderate-to-severe-pediatric-atopic-dermatitis-patient-and-caregiver-centered-approaches-to-improve-outcomes/35848/ On-demand webcast of expert faculty presentation on improving outcomes for pediatric patients with atopic dermatitis, including strategies for implementing systemic therapies and using patient-reported/caregiver-reported outcomes to deliver person-centered care.=
CME credits: 1.00 Valid until: 11-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/raising-the-bar-on-obesity-management-in-psoriasis-and-psoriatic-arthritis-a-collaborative-learning-experience-for-dermatology-and-rheumatology-healthcare-professionals/35849/ On-demand webcast of expert faculty presentation and case discussion on managing obesity care in patients with psoriasis or psoriatic arthritis for dermatology and rheumatology healthcare professionals. =
CME credits: 1.00 Valid until: 02-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-latest-in-stroke-risk-reduction-strategies-are-your-patients-protected/35860/ Listen to expert faculty discuss the role of GLP-1RAs in reducing stroke risk for patients with type 2 diabetes in this on-demand webcast with accompanying slides=
CME credits: 0.50 Valid until: 11-06-2026 Claim your CME credit at https://reachmd.com/programs/cme/integrating-iv-iron-into-cancer-care-an-expert-overview-of-best-practices/35585/ Designed as a dynamic, intensive, and innovative web-based activity, this session will take learners on an in-depth exploration of cancer-related anemia (CRA) and chemotherapy-induced anemia (CIA) as disease states of vast clinical significance, emphasizing the robust prevalence, pathophysiology, and patient burden of CRA/CIA, as well as the prominent role of iron deficiency (ID) in their pathogenesis. Built upon on this foundation, expert faculty will guide attendees through a succinct but comprehensive review of the IV iron evidentiary base in CRA/CIA, including clinical trials, systematic reviews and meta-analyses, and the latest expert consensus guideline recommendations from the NCCN, ASCO/ASH, and ESMO. Practical clinical pearls for safely and effectively implementing IV iron into the real-world hematology/oncology clinic will be emphasized. =
CME credits: 0.25 Valid until: 10-06-2026 Claim your CME credit at https://reachmd.com/programs/cme/innovative-approaches-to-managing-ckm-syndrome-and-hfmrefhfpef/29912/ Listen to Dr. Riccardo Inciardi's summary from the ESC Preventive Cardiology 2025 meeting, where he highlights new therapies reshaping the management of cardio-kidney-metabolic (CKM) syndrome and heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). Watch as he breaks down the latest clinical trial data showing that SGLT2 inhibitors, GLP-1 receptor agonists, and the nonsteroidal MRA finerenone can meaningfully reduce hospitalizations, kidney disease progression, and cardiovascular mortality. A real-life patient case illustrates how combining these therapies—under the care of a multidisciplinary team—can transform outcomes.=
CME credits: 1.00 Valid until: 10-06-2026 Claim your CME credit at https://reachmd.com/programs/cme/where-does-this-patient-land-making-sense-of-risk-and-ldl-c-goals/35815/ Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.
CME credits: 1.00 Valid until: 10-06-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-dose-matters-optimizing-statin-intensity-in-ascvd-management/35816/ Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.
CME credits: 1.00 Valid until: 10-06-2026 Claim your CME credit at https://reachmd.com/programs/cme/expanding-access-alternative-models-for-delivering-lipid-lowering-therapy/35817/ Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.
CME credits: 1.00 Valid until: 10-06-2026 Claim your CME credit at https://reachmd.com/programs/cme/when-and-why-to-use-cac-scoring/35818/ Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.